查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971316

他汀類藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭格局分類，2021-2031年

Statin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Synthetic statin, Natural statin), By End-user (Hospitals & Clinics, Ambulatory Surgical Centers, others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球他汀類藥物市場預計將從 2025 年的 29.2 億美元成長到 2031 年的 34.6 億美元，複合年成長率為 2.87%。

他汀類藥物透過抑制HMG-CoA還原酶來降低低密度脂蛋白膽固醇水平，從而預防心血管事件。這一市場擴張的主要驅動力是全球心血管疾病發生率的上升以及老年人口不斷成長，他們需要進行預防性血脂管理。例如，美國心臟協會（AHA）估計，到2024年，美國約有48.6%的成年人將患有某種形式的心血管疾病，凸顯了醫療保健領域對有效膽固醇調節療法的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 29.2億美元
市場規模：2031年 34.6億美元
複合年成長率：2026-2031年 2.87%
成長最快的細分市場 合成他汀類藥物
最大的市場 北美洲

儘管市場需求強勁，但與他汀類藥物使用相關的副作用報告，例如肌肉疼痛和血糖值升高，正在阻礙市場成長。這些不良反應往往導致患者依從性下降和治療中斷，對全球他汀類藥物市場的持續擴張構成重大挑戰。因此，由於耐受性問題導致的治療中斷風險仍然是該市場積極成長的主要障礙，而疾病的高發生率則支撐了市場的正面成長。

市場促進因素

心血管疾病和血脂異常症的日益普遍是全球他汀類藥物市場的主要驅動力，因為這需要更廣泛的藥物干預來管理患者的健康。高膽固醇症是缺血性心臟疾病和中風的重要危險因素，促使醫療保健提供者將降血脂藥物作為基本的預防措施。美國疾病管制與預防中心 (CDC) 於 2024 年 11 月發布的第 515 號數據簡報強調了這一趨勢，該簡報報告稱，在 2021 年 8 月至 2023 年 8 月期間，約有 11.3% 的 20 歲及以上美國成年人的總膽固醇水平達到超過 240 mg/dL。這確保了需要治療的患者數量持續成長，從而保障了製造商穩定的收入。

同時，社會快速老化正成為一個重要的人口因素，因為心血管疾病的風險會隨著老齡化的成長而顯著增加。老年人通常需要管理慢性疾病，並且是降膽固醇藥物的最大消費族群。根據聯合國人口基金（UNFPA）2024年6月發布的題為《老化》的報導，到2024年，全球65歲及以上人口的比例將達到10.3%，幾乎是1974年以來的兩倍。這種人群結構的變化與處方量的增加直接相關。英國國家醫療服務體系（NHS）商業服務的一份報告顯示，Atorvastatin是2024年英格蘭處方量最大的化學品，在2023/2024會計年度的處方量達到了6500萬片。

市場挑戰

全球他汀類藥物市場成長的主要挑戰是患者依從性低和治療中斷，尤其是由於肌肉疼痛和血糖值升高等副作用。當患者出現這些不良反應時，他們往往會停止用藥或未能遵循處方治療方案，這種趨勢會擾亂製藥業持續獲利所必需的長期處方週期，從而直接導致市場規模萎縮。此外，對這些副作用的擔憂也會造成心理障礙，阻礙患者開始治療，導致合格的患者即使有控制血脂的臨床需求，也會延遲或拒絕他汀類藥物治療。

這一障礙造成了潛在受益於治療的患者群體與實際接受治療的患者數量之間存在顯著差距。根據歐洲心臟學會2024年的數據，約有21.8%的高風險或極高風險心血管風險患者未接受任何降血脂治療。這項統計數據凸顯了耐受性和依從性問題如何有效地阻礙了市場滲透，使該行業無法充分利用全球日益成長的心血管保護需求。

市場趨勢

固定劑量組合藥物製劑（FDC）的日益普及，特別是他汀類藥物與ezetimibe的聯合製劑，使得在不增加他汀類藥物劑量的情況下也能有效降低血脂。這種策略在獲得更佳臨床療效的同時，也能減輕高劑量單藥治療帶來的副作用。 News-Medical.net 於 2025 年 3 月發表的Meta分析顯示，與ezetimibe汀類藥物單藥治療相比，依折麥布聯合高劑量他汀類藥物可顯著降低全因死亡風險 19%。這促使製藥公司優先研發此類雙效製劑，以滿足有效控制膽固醇的需求。

同時，心血管複方製劑的出現正在改變二級預防的格局，它將他汀類藥物、降血壓藥和阿斯匹靈整合到單劑量製劑中。這一趨勢可望透過簡化複雜的日常用藥流程和提高患者依從性，顯著降低全球疾病負擔。根據 tctmd.com 網站 2025 年 7 月發布的報告顯示，到 2050 年，此類單藥複方製劑的廣泛應用可在全球範圍內預防多達 2900 萬人死亡。因此，製造商正在加速投資研發這些多機制產品，旨在從預防醫學領域獲得長期效益。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球他汀類藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（合成他汀類藥物、天然他汀類藥物）
    • 依最終使用者（醫院/診所、門診手術中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美他汀類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲他汀類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區他汀類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲他汀類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲他汀類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球他汀類藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Ltd.
  • Amgen Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Biocon Ltd.
  • Concord Biotech Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21811

The Global Statin Market is projected to expand from USD 2.92 Billion in 2025 to USD 3.46 Billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 2.87%. Statins are pharmaceutical agents that inhibit HMG-CoA reductase to lower low-density lipoprotein cholesterol levels and prevent cardiovascular events. This market expansion is largely driven by the increasing global burden of cardiovascular diseases and a growing geriatric population that requires preventative lipid management. For instance, the American Heart Association estimated in 2024 that approximately 48.6 percent of adults in the United States suffered from some form of cardiovascular disease, underscoring the persistent demand for effective cholesterol-regulating treatments within the healthcare sector.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.92 Billion
Market Size 2031USD 3.46 Billion
CAGR 2026-20312.87%
Fastest Growing SegmentSynthetic Statin
Largest MarketNorth America

Despite this strong demand, market progression faces obstacles due to documented side effects associated with statin use, such as muscle pain and elevated blood sugar levels. These adverse reactions often lead to patient non-adherence or the discontinuation of therapy, presenting a significant challenge to the sustained expansion of the global statin market. Consequently, the potential for treatment cessation due to intolerance remains a critical hurdle that counters the otherwise positive market trajectory fueled by disease prevalence.

Market Driver

The escalating prevalence of cardiovascular diseases and dyslipidemia serves as the primary catalyst propelling the Global Statin Market, as these conditions require extensive pharmacological intervention to manage patient health. High cholesterol levels act as a critical risk factor for ischemic heart disease and stroke, compelling healthcare providers to prescribe lipid-lowering agents as a fundamental preventive measure. This trend is highlighted by the Centers for Disease Control and Prevention in their November 2024 'NCHS Data Brief No. 515', which noted that approximately 11.3 percent of United States adults aged 20 and older had high total cholesterol levels of 240 mg/dL or more between August 2021 and August 2023, ensuring a continuous stream of patients requiring therapy and securing steady revenue for manufacturers.

Concurrently, the rapid expansion of the global geriatric population functions as a powerful demographic driver, given that susceptibility to cardiovascular ailments increases significantly with age. Older adults often require chronic disease management, making them the largest consumer segment for cholesterol-regulating medications. According to the United Nations Population Fund's June 2024 article 'Ageing', the worldwide share of people aged 65 years and older reached 10.3 percent in 2024, a figure that has nearly doubled since 1974. This demographic shift translates directly into higher prescription volumes, as evidenced by the NHS Business Services Authority reporting that Atorvastatin was the most dispensed chemical substance in England in 2024, with 65 million items provided during the 2023/2024 financial year.

Market Challenge

The primary challenge restricting the growth of the Global Statin Market is patient non-adherence and the discontinuation of therapy triggered by documented side effects, specifically muscle pain and increased blood sugar levels. When patients experience these adverse reactions, they frequently cease their medication or fail to follow prescribed regimens, a pattern that directly erodes market volume by terminating the long-term prescription cycles essential for the pharmaceutical sector's recurring revenue. Furthermore, the fear of these side effects creates a psychological barrier to initiating treatment, causing eligible patients to delay or refuse statin therapy despite the clinical necessity for lipid management.

This impediment creates a significant gap between the addressable patient population and the actual volume of treated individuals. Data from the European Society of Cardiology in 2024 highlighted that approximately 21.8 percent of patients at high or very high cardiovascular risk were not receiving any lipid-lowering treatment. This statistic underscores how intolerance and adherence issues effectively hamper market penetration, preventing the industry from fully capitalizing on the rising global demand for cardiovascular protection.

Market Trends

The increasing adoption of Fixed-Dose Combination (FDC) therapies, particularly those pairing statins with ezetimibe, enables aggressive lipid lowering without maximizing statin dosages. This strategy mitigates the side effects associated with high-dose monotherapy while delivering superior clinical outcomes. According to a meta-analysis reported by News-Medical.net in March 2025, combining ezetimibe with high-dose statins resulted in a significant 19 percent reduction in the risk of death from any cause compared to statins alone, prompting pharmaceutical companies to prioritize these dual-action formulations to meet the demand for effective cholesterol management.

Simultaneously, the emergence of cardiovascular polypills is transforming secondary prevention by consolidating statins, antihypertensives, and aspirin into single-dosage forms. This trend addresses patient non-adherence by simplifying complex daily regimens, offering substantial potential to reduce the global disease burden. As noted by tctmd.com in July 2025, the widespread adoption of such single-pill combination therapies could prevent up to 29 million deaths globally by 2050, leading manufacturers to increasingly invest in these multi-mechanism products to secure long-term revenue from the preventative care sector.

Key Market Players

  • Abbott Laboratories Ltd.
  • Amgen Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Biocon Ltd.
  • Concord Biotech Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Statin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Statin Market, By Type

  • Synthetic statin
  • Natural statin

Statin Market, By End-user

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • others

Statin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Statin Market.

Available Customizations:

Global Statin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Statin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Synthetic statin, Natural statin)
    • 5.2.2. By End-user (Hospitals & Clinics, Ambulatory Surgical Centers, others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Statin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Statin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End-user
    • 6.3.2. Canada Statin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End-user
    • 6.3.3. Mexico Statin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End-user

7. Europe Statin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Statin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End-user
    • 7.3.2. France Statin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End-user
    • 7.3.3. United Kingdom Statin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End-user
    • 7.3.4. Italy Statin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End-user
    • 7.3.5. Spain Statin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End-user

8. Asia Pacific Statin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End-user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Statin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End-user
    • 8.3.2. India Statin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End-user
    • 8.3.3. Japan Statin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End-user
    • 8.3.4. South Korea Statin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End-user
    • 8.3.5. Australia Statin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End-user

9. Middle East & Africa Statin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End-user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Statin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End-user
    • 9.3.2. UAE Statin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End-user
    • 9.3.3. South Africa Statin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End-user

10. South America Statin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End-user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Statin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End-user
    • 10.3.2. Colombia Statin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End-user
    • 10.3.3. Argentina Statin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End-user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Statin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. AstraZeneca Plc
  • 15.4. Aurobindo Pharma Ltd.
  • 15.5. Biocon Ltd.
  • 15.6. Concord Biotech Ltd.
  • 15.7. Merck and Co. Inc.
  • 15.8. Novartis AG
  • 15.9. Pfizer Inc.
  • 15.10. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer